MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i>-mutated advanced pancreatic ductal adenocarcinoma (PDAC).Maahum Mehdi, Mandana Kamgar, James P. Thomas et al.|Journal of Clinical Oncology|2022Cited by 7
Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case seriesMaahum Mehdi, Mandana Kamgar, Aniko Szabo et al.|Therapeutic Advances in Medical Oncology|2024Cited by 5